Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran
10.1016/j.apjtb.2015.12.020
- Author:
Kazem BAESI
1
;
Majedeh MORADBEIGI
2
;
Mehrdad RAVANSHAD
3
;
Ashrafolnesa BAGHBAN
3
Author Information
1. Hepatitis and AIDS Department, Pasteur Institute of Iran
2. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences
3. Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University
- Publication Type:Journal Article
- Keywords:
Highly active antiretroviral therapy;
HIV;
Protease inhibitor;
Transmitted drug resistance
- From:Asian Pacific Journal of Tropical Biomedicine
2016;6(5):451-454
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To survey the level and patterns of reverse transcriptase-based drug resistance and subtype distribution among antiretroviral-treated HIV-infected patients receiving only reverse transcriptase inhibitors in Iran. Methods: A total of 25 samples of antiretroviral therapy experienced patients with no history of using protease inhibitors were collected. After RNA extraction, reverse transcriptase-nested PCR was performed. The final products were sequenced and then analysed for drug-resistant mutations and subtypes. Results: No drug resistant mutations were observed among the 25 subjects. The results showed the following subtypes among patients: CRF 35_AD (88%), CRF 28_BF (8%), and CRF 29_BF (4%). Conclusions: A significant increase in drug resistance has been noted in recently-infected patients worldwide. Subtype distributions are needed to perform properly-designed surveillance studies to continuously monitor rates and patterns of transmitted drug resistance and subtypes to help guide therapeutic approaches and limit transmission of these variants.
